Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary hypothesis is that INT-747 will cause a reduction in alkaline phosphatase levels in Primary Biliary Cirrhosis patients, over a 12 week treatment period, as compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Intercept Pharmaceuticals
• Treatments: Chenodeoxycholic Acid; Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

• Male or female age 18 to 70 years.

• Stable dose of ursodeoxycholic acid (URSO, UDCA) for at least 6 months prior to screening.

• Female patients must be postmenopausal, surgically sterile, or prepared to use 2 methods of contraception with all sexual partners during the study and for 14 days after the end of dosing.

• Male patients must be prepared to use 2 methods of contraception with all sexual partners during the study and for 14 days after the end of the dosing.

• Proven or likely PBC, as demonstrated by the patient presenting with at least 2 of the following 3 diagnostic factors:

1. History of increased AP levels for at least 6 months prior to Day 0

2. Positive AMA titer (>1:40 titer on immunofluorescence or M2 positive by ELISA) or PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive)

3. Liver biopsy consistent with PBC.

• Screening AP value between 1.5 and 10 × ULN.

Exclusion Criteria:

• Administration of the following drugs at any time during the 3 months prior to screening for the study: colchicine, methotrexate, azathioprine, or systemic corticosteroids.

• Screening conjugated (direct) bilirubin >2 × ULN.

• Screening ALT or AST >5 × ULN.

• Screening serum creatinine >1.5 mg/dL (133 mol/L).

• History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy, or poorly controlled ascites).

• History or presence of other concomitant liver diseases including hepatitis due to hepatitis B or C virus (HCV, HBV) infection, primary sclerosing cholangitis (PSC), alcoholic liver disease, definite autoimmune liver disease or biopsy proven nonalcoholic steatohepatitis (NASH).

• Pregnancy.